Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01832753 · ClinicalTrials.gov registry record · NA

Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

A NA study of Down Syndrome and Subclinical Hypothyroidism, sponsored by Children's Hospital of Philadelphia.

Completed
Registry status
NA
Development phase
12
Enrollment target
2
Study locations

NCT01832753 is a NA study of Down Syndrome and Subclinical Hypothyroidism that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 12 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01832753, a NA study of Down Syndrome and Subclinical Hypothyroidism, has completed, sponsored by Children's Hospital of Philadelphia.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.

Interventions

  • DRUG Levothyroxine

Study Locations (2)

District of Columbia

  • Children's National Medical Center - Washington D.C.

Pennsylvania

  • The Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2013-01
Est. Completion 2017-10-18
Phase NA

Sponsor

Children's Hospital of Philadelphia

431 total trials

What the Registry Record Tells You About NCT01832753

The ClinicalTrials.gov registry entry for NCT01832753 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (100% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Down Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Levothyroxine is the first listed.

NCT01832753 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01832753 about?

NCT01832753 is a clinical study titled "Treatment Trial of Subclinical Hypothyroidism in Down Syndrome". The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic healt...

What is the current status of trial NCT01832753?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2013-01. Estimated completion is 2017-10-18.

What conditions does trial NCT01832753 study?

This clinical trial studies the following conditions: Down Syndrome, Subclinical Hypothyroidism.

What interventions are being tested in trial NCT01832753?

The interventions under investigation include: Levothyroxine (DRUG).

Who is sponsoring clinical trial NCT01832753?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01832753 being conducted?

This trial has 2 study locations across District of Columbia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.